SUPN Supernus Pharmaceuticals
- 30.845
- +0.425+1.40%
Supernus Pharmaceuticals News
Supernus Pharmaceuticals | ARS: Annual Report to Security Holders
Supernus Pharmaceuticals | DEF 14A: Definitive information statements
Supernus Pharmaceuticals | DEFA14A: Others
Supernus Pharmaceuticals | 8-K: Current report
Supernus Pharmaceuticals | 8-K: Current report
Supernus Pharmaceuticals | 8-K: Current report
Supernus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bhatt Padmanabh P.
Supernus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bhatt Padmanabh P.
Supernus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bhatt Padmanabh P.
Supernus Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Supernus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bhatt Padmanabh P.
Supernus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bhatt Padmanabh P.
Supernus Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Supernus Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Supernus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Khattar Jack A.
Supernus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Mottola Frank
Supernus Pharmaceuticals | 8-K: Current report
Supernus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bhatt Padmanabh P.
Supernus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GEMAYEL GEORGES
Supernus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director SIEBERT JOHN M
Analysis
Price Target
No Data
